查看购物车
  • Traditional Chinese
  • English
  • Japanese
2021-2031 年欧洲药物警戒和药物安全软体市场报告（范围、细分、动态和竞争分析）
市场调查报告书
商品编码
1819689

2021-2031 年欧洲药物警戒和药物安全软体市场报告（范围、细分、动态和竞争分析）

Europe Pharmacovigilance and Drug Safety Software Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 224 Pages | 订单完成后即时交付

价格

2023 年欧洲药物警戒和药物安全软体市场价值约为 5,238 万美元，预计到 2031 年将成长到 8,467 万美元，在此期间的年复合成长率(CAGR) 为 6.2%。

药物警戒全球化：市场成长的催化剂

药物警戒涉及对药物不良反应 (ADR) 的监测和评估，是药品监管、临床实践和公共卫生计划的关键环节。药物警戒的全球化正在促进各利益相关者（包括监管机构、医疗保健提供者和製药公司）之间加强合作。例如，欧洲药品管理局 (EMA) 日益强调药品监管机构之间国际合作的重要性，重点在于药品安全、检查和相关资讯交流。这种合作框架不仅促进了资料共享，也增进了对药品安全性的整体理解。

随着企业力求利用这些全球网络，对能够跨境有效运作的综合药物警戒解决方案的需求日益凸显。世界各国政府正与本国监管机构合作实施药物警戒计划，并承认药物警戒在确保药品安全方面的重要作用。各国对药物警戒的认识不断提高，并纷纷采用最佳实践，这显着增加了对专业软体解决方案的需求。一个显着的例子是义大利医疗机构，该机构于2022年6月启动了国家药物警戒网路 (RNF)，以检测疑似不良反应 (ADR)。该系统整合了管理和分析ADR报告的先进功能，确保对药品安全性进行准确评估。此外，欧洲各国普遍使用的EudraVigilance系统可以产生疑似ADR报告，进一步加强了药物警戒工作。

药物警戒的全球化也促进了跨国合作。一些欧洲倡议，例如比荷卢经济联盟、北欧合作组织和《瓦莱塔宣言》，旨在改善患者获得创新疗法的管道。例如，比荷卢经济联盟倡议加强了比利时、荷兰、卢森堡、奥地利和爱尔兰之间的合作，使中等收入国家能够协商更优惠的药品定价并分享政策专业知识。这些合作努力支持全面的卫生技术评估，并提高药品行销的透明度。建立一个能够在全球范围内管理和报告药品不良反应的强大药物警戒系统，对于推进药物警戒的全球化至关重要，从而推动药物警戒和药物安全软体市场的成长。

欧洲药物警戒与药品安全软体市场概况

欧洲对药物警戒和药物安全软体的需求不断增长，这可归因于多种因素，包括严格的监管要求、药品审批数量的增加、对病人安全的高度重视以及技术进步。欧盟的药物警戒框架是全球最完善的框架之一，EMA 等监管机构执行严格的药物警戒标准，这要求采用先进的软体解决方案。欧盟药物警戒指令 (2010/84/EU) 和法规 (EU) No 1235/2010 引入了更严格的药品不良反应 (ADR) 监测规则，强制公司即时报告安全资料，并增加了对能够处理大量资料的高效软体系统的需求。

欧洲製药业新药审批数量激增，进一步推动了对药物警戒和药物安全软体的需求，以有效监测安全资料。例如，2023年第二季度，欧洲药品管理局（EMA）和美国食品药物管理局（FDA）批准了超过21种新的肿瘤药物。随着越来越多的产品进入市场，製药公司需要强大的软体解决方案来确保这些药物的安全性和有效性。甲骨文公司等大型公司正大力投资药物警戒软体，以增强其对新核准产品的安全监测能力，并利用Oracle Argus Safety和Veeva Vault Safety等平台进行有效的不良事件管理。

此外，欧洲各国政府正在实施合规措施以保护软体资料，尤其是在欧盟《一般资料保护规范》（GDPR）推出后。该条例规定，药物警戒和药物安全软体不仅要符合监管标准，还要确保营运效率，同时保护资料隐私。遵守GDPR对于维护患者和监管机构的信任至关重要，从而促进药物警戒软体在欧洲的普及。

人工智慧 (AI)、机器学习 (ML) 和其他先进技术的融合正在彻底改变药物警戒流程。这些创新促进了自动化资料处理、即时讯号检测和进阶分析，从而简化了安全资料管理和法规合规性。例如，ArisGlobal 的 LifeSphere 平台利用人工智慧实现案例处理自动化并增强讯号检测能力，进一步推动了欧洲对药物警戒和药物安全软体的需求。

市场区隔分析

欧洲药物警戒和药物安全软体市场根据各种标准进行细分，包括产品、部署、企业规模、形式、功能、最终用户和国家。

  • 产品：市场分为软体和服务，其中软体部分在 2023 年将占据更大的份额。
  • 部署：市场分为云端解决方案和本地解决方案，其中云端解决方案在 2023 年占主导地位。
  • 企业规模：市场分为大型企业和中小企业，其中大型企业占有相当大的份额。
  • 形式：市场分为标准解决方案和客製化解决方案，其中标准解决方案在市场份额中领先。
  • 功能：市场包括讯号和风险管理、问题追踪、案例管理等，其中讯号和风险管理是最大的部分。
  • 最终用户：市场分为製药和生物技术公司、合约研究组织和 BPO 公司，其中製药和生物技术公司处于领先地位。
  • 国家：市场分为德国、法国、英国、义大利、西班牙和欧洲其他地区，其中德国在 2023 年占据市场份额的主导地位。

市场关键参与者

欧洲药物警戒和药物安全软体市场的领先公司包括 Veeva Systems Inc、IQVIA Holdings Inc、AB Cube SAS、ArisGlobal LLC、Oracle Corp、Max Application、ICON Plc、Cognizant Technology Solutions Corp、Accenture Plc、Syneos Health Inc、Genpact Ltd.、Laboratory Corp of America Holdings、Parexsa Technologies、Qline）。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：欧洲药物警戒与药品安全软体市场格局

  • 4.1 概述
  • 生态系分析
    • 软体/服务提供者：
    • 系统整合商：
    • 监理机构：
    • 最终用户：
    • 价值链中的供应商列表

第五章：欧洲药物警戒与药品安全软体市场－关键市场动态

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响：

第六章：欧洲药物警戒与药品安全软体市场 - 分析

  • 2021-2031年欧洲药物警戒与药物安全软体市场收入
  • 欧洲药物警戒与药品安全软体市场预测分析

第七章：欧洲药物警戒与药品安全软体市场分析-依产品

  • 软体
  • 服务

第 8 章：欧洲药物警戒与药品安全软体市场分析 - 按部署

  • 云
  • 本地

第九章：欧洲药物警戒与药品安全软体市场分析－依企业规模

  • 大型企业
  • 中小企业

第 10 章：欧洲药物警戒和药品安全软体市场分析 - 按形式

  • 标准
  • 客製化

第 11 章：欧洲药物警戒与药品安全软体市场分析 - 按功能

  • 讯号和风险管理
  • 问题跟踪和不良事件跟踪
  • 案件管理
  • 临床安全管理与临床试验安全
  • 品质与合规
  • 医学写作
  • 审计支援和培训合规性
  • 医疗保健分析
  • 其他的

第 12 章：欧洲药物警戒和药品安全软体市场分析 - 按最终用户

  • 製药和生物技术公司
  • 合约研究组织
  • 业务流程外包（BPO）公司
  • 其他的

第 13 章：欧洲药物警戒与药品安全软体市场 - 国家分析

  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区

第 14 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第十五章：产业格局

  • 概述
  • 市场倡议
  • 伙伴关係与合作

第 16 章：公司简介

  • ArisGlobal LLC
  • Max Application
  • Oracle Corp
  • Veeva Systems Inc
  • IQVIA Holdings Inc
  • ICON Plc
  • Cognizant Technology Solutions Corp
  • Accenture Plc
  • Syneos Health Inc
  • Genpact Ltd.
  • AB Cube S.A.S.
  • Laboratory Corp of America Holdings
  • Parexel International Corp
  • Qinecsa Solutions
  • Clinevo Technologies

第 17 章：附录

Product Code: TIPRE00022771

The pharmacovigilance and drug safety software market in Europe was valued at approximately US$ 52.38 million in 2023, with projections indicating it will grow to US$ 84.67 million by 2031, reflecting a compound annual growth rate (CAGR) of 6.2% during this period.

Globalization of Pharmacovigilance: A Catalyst for Market Growth

Pharmacovigilance, which involves the monitoring and assessment of adverse drug reactions (ADRs), is a critical aspect of drug regulation, clinical practice, and public health initiatives. The globalization of pharmacovigilance is fostering enhanced collaboration among various stakeholders, including regulatory authorities, healthcare providers, and pharmaceutical companies. For example, the European Medicines Agency (EMA) has increasingly emphasized the importance of international cooperation among pharmaceutical regulators, focusing on medicine safety, inspections, and the exchange of pertinent information. This collaborative framework not only facilitates data sharing but also improves the overall understanding of drug safety profiles.

As companies aim to capitalize on these global networks, the demand for integrated pharmacovigilance solutions that can function effectively across borders is becoming more pronounced. Governments worldwide are implementing pharmacovigilance programs in partnership with their national regulatory bodies, recognizing the vital role of pharmacovigilance in ensuring drug safety. The growing awareness and adoption of best practices in pharmacovigilance across various countries have significantly increased the demand for specialized software solutions. A notable example is Italy's Medical Agency, which launched the National Pharmacovigilance Network (RNF) in June 2022 to detect suspected ADRs. This system incorporates advanced functionalities for managing and analyzing ADR reports, ensuring accurate assessments of medicine safety. Additionally, the EudraVigilance System, utilized across European nations, generates reports on suspected ADRs, further enhancing pharmacovigilance efforts.

The globalization of pharmacovigilance also promotes cross-border collaboration. Several European initiatives, such as BeNeLuxA, the Nordic collaborations, and the Valletta Declaration, aim to improve patient access to innovative therapies. The BeNeLuxA initiative, for instance, enhances cooperation among Belgium, the Netherlands, Luxembourg, Austria, and Ireland, allowing middle-income countries to negotiate better drug pricing and share policy expertise. These collaborative efforts support comprehensive health technology assessments and improve transparency in pharmaceutical marketing. The establishment of robust pharmacovigilance systems capable of managing and reporting ADRs on a global scale is essential for advancing the globalization of pharmacovigilance, thereby driving the growth of the pharmacovigilance and drug safety software market.

Overview of the Europe Pharmacovigilance and Drug Safety Software Market

The increasing demand for pharmacovigilance and drug safety software in Europe can be attributed to several factors, including stringent regulatory requirements, a rise in drug approvals, a heightened focus on patient safety, and technological advancements. The EU's pharmacovigilance framework is among the most sophisticated globally, with regulatory bodies like the EMA enforcing rigorous pharmacovigilance standards that necessitate the adoption of advanced software solutions. The EU Pharmacovigilance Directive (2010/84/EU) and Regulation (EU) No 1235/2010 have introduced stricter monitoring rules for ADRs, compelling companies to report safety data in real-time and increasing the need for efficient software systems capable of handling large data volumes.

The European pharmaceutical sector has witnessed a surge in new drug approvals, further driving the demand for pharmacovigilance and drug safety software to monitor safety data effectively. For instance, in the second quarter of 2023, the EMA and the US FDA approved over 21 new oncology drugs. As more products enter the market, pharmaceutical companies require robust software solutions to ensure the safety and efficacy of these drugs. Major companies, such as Oracle Corp, are heavily investing in pharmacovigilance software to enhance their safety monitoring capabilities for newly approved products, utilizing platforms like Oracle Argus Safety and Veeva Vault Safety for effective adverse event management.

Moreover, European governments are implementing compliance measures to protect software data, particularly with the introduction of the EU General Data Protection Regulation (GDPR). This regulation mandates that pharmacovigilance and drug safety software not only meet regulatory standards but also ensure operational efficiency while safeguarding data privacy. Adhering to GDPR is crucial for maintaining trust with patients and regulatory bodies alike, thereby boosting the adoption of pharmacovigilance software across Europe.

The integration of artificial intelligence (AI), machine learning (ML), and other advanced technologies is revolutionizing pharmacovigilance processes. These innovations facilitate automated data processing, real-time signal detection, and advanced analytics, simplifying the management of safety data and compliance with regulatory requirements. For example, ArisGlobal's LifeSphere platform leverages AI to automate case processing and enhance signal detection capabilities, further driving the demand for pharmacovigilance and drug safety software in Europe.

Market Segmentation Analysis

The Europe pharmacovigilance and drug safety software market is segmented based on various criteria, including offering, deployment, enterprise size, form, functionality, end user, and country.

  • Offering: The market is divided into software and services, with the software segment holding a larger share in 2023.
  • Deployment: The market is categorized into cloud and on-premises solutions, with cloud solutions dominating in 2023.
  • Enterprise Size: The market is segmented into large enterprises and SMEs, with large enterprises holding a significant share.
  • Form: The market is classified into standard and customized solutions, with standard solutions leading in market share.
  • Functionality: The market includes signal and risk management, issue tracking, case management, and more, with signal and risk management being the largest segment.
  • End User: The market is divided into pharmaceutical and biotechnology companies, contract research organizations, and BPO firms, with pharmaceutical and biotechnology companies leading.
  • Country: The market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe, with Germany dominating the market share in 2023.

Key Players in the Market

Leading companies in the Europe pharmacovigilance and drug safety software market include Veeva Systems Inc, IQVIA Holdings Inc, AB Cube S.A.S., ArisGlobal LLC, Oracle Corp, Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health Inc, Genpact Ltd., Laboratory Corp of America Holdings, Parexel International Corp, Qinecsa Solutions, and Clinevo Technologies.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Pharmacovigilance and Drug Safety Software Market Landscape

  • 4.1 Overview
  • 4.2 Ecosystem Analysis
    • 4.2.1 Software/Service Providers:
    • 4.2.2 System Integrators:
    • 4.2.3 Regulatory Bodies:
    • 4.2.4 End-Users:
    • 4.2.5 List of Vendors in the Value Chain

5. Europe Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics

  • 5.1 Market Drivers
  • 5.2 Market Restraints
  • 5.3 Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact of Drivers and Restraints:

6. Europe Pharmacovigilance and Drug Safety Software Market - Analysis

  • 6.1 Europe Pharmacovigilance and Drug Safety Software Market Revenue (US$ Thousand), 2021-2031
  • 6.2 Europe Pharmacovigilance and Drug Safety Software Market Forecast Analysis

7. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Offering

  • 7.1 Software
    • 7.1.1 Overview
    • 7.1.2 Software: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 7.2 Services
    • 7.2.1 Overview
    • 7.2.2 Services: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Deployment

  • 8.1 Cloud
    • 8.1.1 Overview
    • 8.1.2 Cloud: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.2 On Premises
    • 8.2.1 Overview
    • 8.2.1 On Premises: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Enterprise Size

  • 9.1 Large Enterprises
    • 9.1.1 Overview
    • 9.1.2 Large Enterprises: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 9.2 SMEs
    • 9.2.1 Overview
    • 9.2.1 SMEs: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

10. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Form

  • 10.1 Standard
    • 10.1.1 Overview
    • 10.1.2 Standard: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 10.2 Customized
    • 10.2.1 Overview
    • 10.2.1 Customized: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

11. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Functionality

  • 11.1 Signal and Risk Management
    • 11.1.1 Overview
    • 11.1.2 Signal and Risk Management: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.2 Issue Tracking and Adverse Event Tracking
    • 11.2.1 Overview
    • 11.2.2 Issue Tracking and Adverse Event Tracking: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.3 Case Management
    • 11.3.1 Overview
    • 11.3.2 Case Management: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.4 Clinical Safety Management and Clinical Trial Safety
    • 11.4.1 Overview
    • 11.4.1 Clinical Safety Management and Clinical Trial Safety: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.5 Quality and Compliance
    • 11.5.1 Overview
    • 11.5.1 Quality and Compliance: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.6 Medical Writing
    • 11.6.1 Overview
    • 11.6.1 Medical Writing: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.7 Audit Support and Training Compliance
    • 11.7.1 Overview
    • 11.7.1 Audit Support and Training Compliance: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.8 Healthcare Analytics
    • 11.8.1 Overview
    • 11.8.1 Healthcare Analytics: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.9 Others
    • 11.9.1 Overview
    • 11.9.1 Others: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

12. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by End User

  • 12.1 Pharmaceutical and Biotechnology Companies
    • 12.1.1 Overview
    • 12.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 12.2 Contract Research Organizations
    • 12.2.1 Overview
    • 12.2.1 Contract Research Organizations: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 12.3 Business Process Outsourcing (BPO) Firms
    • 12.3.1 Overview
    • 12.3.1 Business Process Outsourcing (BPO) Firms: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 12.4 Others
    • 12.4.1 Overview
    • 12.4.1 Others: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

13. Europe Pharmacovigilance and Drug Safety Software Market - Country Analysis

  • 13.1 Europe
    • 13.1.1 Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast Analysis - by Country
      • 13.1.1.1 Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast Analysis - by Country
      • 13.1.1.2 Germany: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 13.1.1.2.1 Germany: Europe Pharmacovigilance and Drug Safety Software Market Share - by Offering
        • 13.1.1.2.2 Germany: Europe Pharmacovigilance and Drug Safety Software Market Share - by Deployment
        • 13.1.1.2.3 Germany: Europe Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
        • 13.1.1.2.4 Germany: Europe Pharmacovigilance and Drug Safety Software Market Share - by Form
        • 13.1.1.2.5 Germany: Europe Pharmacovigilance and Drug Safety Software Market Share - by Functionality
        • 13.1.1.2.6 Germany: Europe Pharmacovigilance and Drug Safety Software Market Share - by End User
      • 13.1.1.3 France: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 13.1.1.3.1 France: Europe Pharmacovigilance and Drug Safety Software Market Share - by Offering
        • 13.1.1.3.2 France: Europe Pharmacovigilance and Drug Safety Software Market Share - by Deployment
        • 13.1.1.3.3 France: Europe Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
        • 13.1.1.3.4 France: Europe Pharmacovigilance and Drug Safety Software Market Share - by Form
        • 13.1.1.3.5 France: Europe Pharmacovigilance and Drug Safety Software Market Share - by Functionality
        • 13.1.1.3.6 France: Europe Pharmacovigilance and Drug Safety Software Market Share - by End User
      • 13.1.1.4 United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 13.1.1.4.1 United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market Share - by Offering
        • 13.1.1.4.2 United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market Share - by Deployment
        • 13.1.1.4.3 United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
        • 13.1.1.4.4 United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market Share - by Form
        • 13.1.1.4.5 United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market Share - by Functionality
        • 13.1.1.4.6 United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market Share - by End User
      • 13.1.1.5 Italy: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 13.1.1.5.1 Italy: Europe Pharmacovigilance and Drug Safety Software Market Share - by Offering
        • 13.1.1.5.2 Italy: Europe Pharmacovigilance and Drug Safety Software Market Share - by Deployment
        • 13.1.1.5.3 Italy: Europe Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
        • 13.1.1.5.4 Italy: Europe Pharmacovigilance and Drug Safety Software Market Share - by Form
        • 13.1.1.5.5 Italy: Europe Pharmacovigilance and Drug Safety Software Market Share - by Functionality
        • 13.1.1.5.6 Italy: Europe Pharmacovigilance and Drug Safety Software Market Share - by End User
      • 13.1.1.6 Spain: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 13.1.1.6.1 Spain: Europe Pharmacovigilance and Drug Safety Software Market Share - by Offering
        • 13.1.1.6.2 Spain: Europe Pharmacovigilance and Drug Safety Software Market Share - by Deployment
        • 13.1.1.6.3 Spain: Europe Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
        • 13.1.1.6.4 Spain: Europe Pharmacovigilance and Drug Safety Software Market Share - by Form
        • 13.1.1.6.5 Spain: Europe Pharmacovigilance and Drug Safety Software Market Share - by Functionality
        • 13.1.1.6.6 Spain: Europe Pharmacovigilance and Drug Safety Software Market Share - by End User
      • 13.1.1.7 Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 13.1.1.7.1 Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market Share - by Offering
        • 13.1.1.7.2 Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market Share - by Deployment
        • 13.1.1.7.3 Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
        • 13.1.1.7.4 Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market Share - by Form
        • 13.1.1.7.5 Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market Share - by Functionality
        • 13.1.1.7.6 Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market Share - by End User

14. Competitive Landscape

  • 14.1 Heat Map Analysis by Key Players
  • 14.2 Company Positioning and Concentration

15. Industry Landscape

  • 15.1 Overview
  • 15.2 Market Initiative
  • 15.3 Partnerships and Collaborations

16. Company Profiles

  • 16.1 ArisGlobal LLC
    • 16.1.1 Key Facts
    • 16.1.2 Business Description
    • 16.1.3 Products and Services
    • 16.1.4 Financial Overview
    • 16.1.5 SWOT Analysis
    • 16.1.6 Key Developments
  • 16.2 Max Application
    • 16.2.1 Key Facts
    • 16.2.2 Business Description
    • 16.2.3 Products and Services
    • 16.2.4 Financial Overview
    • 16.2.5 SWOT Analysis
    • 16.2.6 Key Developments
  • 16.3 Oracle Corp
    • 16.3.1 Key Facts
    • 16.3.2 Business Description
    • 16.3.3 Products and Services
    • 16.3.4 Financial Overview
    • 16.3.5 SWOT Analysis
    • 16.3.6 Key Developments
  • 16.4 Veeva Systems Inc
    • 16.4.1 Key Facts
    • 16.4.2 Business Description
    • 16.4.3 Products and Services
    • 16.4.4 Financial Overview
    • 16.4.5 SWOT Analysis
    • 16.4.6 Key Developments
  • 16.5 IQVIA Holdings Inc
    • 16.5.1 Key Facts
    • 16.5.2 Business Description
    • 16.5.3 Products and Services
    • 16.5.4 Financial Overview
    • 16.5.5 SWOT Analysis
    • 16.5.6 Key Developments
  • 16.6 ICON Plc
    • 16.6.1 Key Facts
    • 16.6.2 Business Description
    • 16.6.3 Products and Services
    • 16.6.4 Financial Overview
    • 16.6.5 SWOT Analysis
    • 16.6.6 Key Developments
  • 16.7 Cognizant Technology Solutions Corp
    • 16.7.1 Key Facts
    • 16.7.2 Business Description
    • 16.7.3 Products and Services
    • 16.7.4 Financial Overview
    • 16.7.5 SWOT Analysis
    • 16.7.6 Key Developments
  • 16.8 Accenture Plc
    • 16.8.1 Key Facts
    • 16.8.2 Business Description
    • 16.8.3 Products and Services
    • 16.8.4 Financial Overview
    • 16.8.5 SWOT Analysis
    • 16.8.6 Key Developments
  • 16.9 Syneos Health Inc
    • 16.9.1 Key Facts
    • 16.9.2 Business Description
    • 16.9.3 Products and Services
    • 16.9.4 Financial Overview
    • 16.9.5 SWOT Analysis
    • 16.9.6 Key Developments
  • 16.10 Genpact Ltd.
    • 16.10.1 Key Facts
    • 16.10.2 Business Description
    • 16.10.3 Products and Services
    • 16.10.4 Financial Overview
    • 16.10.5 SWOT Analysis
    • 16.10.6 Key Developments
  • 16.11 AB Cube S.A.S.
    • 16.11.1 Key Facts
    • 16.11.2 Business Description
    • 16.11.3 Products and Services
    • 16.11.4 Financial Overview
    • 16.11.5 SWOT Analysis
    • 16.11.6 Key Developments
  • 16.12 Laboratory Corp of America Holdings
    • 16.12.1 Key Facts
    • 16.12.2 Business Description
    • 16.12.3 Products and Services
    • 16.12.4 Financial Overview
    • 16.12.5 SWOT Analysis
    • 16.12.6 Key Developments
  • 16.13 Parexel International Corp
    • 16.13.1 Key Facts
    • 16.13.2 Business Description
    • 16.13.3 Products and Services
    • 16.13.4 Financial Overview
    • 16.13.5 SWOT Analysis
    • 16.13.6 Key Developments
  • 16.14 Qinecsa Solutions
    • 16.14.1 Key Facts
    • 16.14.2 Business Description
    • 16.14.3 Products and Services
    • 16.14.4 Financial Overview
    • 16.14.5 SWOT Analysis
    • 16.14.6 Key Developments
  • 16.15 Clinevo Technologies
    • 16.15.1 Key Facts
    • 16.15.2 Business Description
    • 16.15.3 Products and Services
    • 16.15.4 Financial Overview
    • 16.15.5 SWOT Analysis
    • 16.15.6 Key Developments

17. Appendix

  • 17.1 About Us
  • 17.2 List of Abbreviations

List Of Tables

  • Table 1. Europe Pharmacovigilance and Drug Safety Software Market Segmentation
  • Table 2. List of Vendors
  • Table 3. Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Table 4. Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Offering
  • Table 5. Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Deployment
  • Table 6. Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Enterprise Size
  • Table 7. Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Form
  • Table 8. Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Functionality
  • Table 9. Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
  • Table 10. Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
  • Table 11. Germany: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Offering
  • Table 12. Germany: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Deployment
  • Table 13. Germany: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Enterprise Size
  • Table 14. Germany: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Form
  • Table 15. Germany: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Functionality
  • Table 16. Germany: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 17. France: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Offering
  • Table 18. France: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Deployment
  • Table 19. France: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Enterprise Size
  • Table 20. France: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Form
  • Table 21. France: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Functionality
  • Table 22. France: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 23. United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Offering
  • Table 24. United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Deployment
  • Table 25. United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Enterprise Size
  • Table 26. United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Form
  • Table 27. United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Functionality
  • Table 28. United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 29. Italy: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Offering
  • Table 30. Italy: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Deployment
  • Table 31. Italy: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Enterprise Size
  • Table 32. Italy: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Form
  • Table 33. Italy: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Functionality
  • Table 34. Italy: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 35. Spain: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Offering
  • Table 36. Spain: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Deployment
  • Table 37. Spain: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Enterprise Size
  • Table 38. Spain: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Form
  • Table 39. Spain: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Functionality
  • Table 40. Spain: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 41. Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Offering
  • Table 42. Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Deployment
  • Table 43. Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Enterprise Size
  • Table 44. Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Form
  • Table 45. Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Functionality
  • Table 46. Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 47. List of Abbreviations

List Of Figures

  • Figure 1. Europe Pharmacovigilance and Drug Safety Software Market Segmentation - Country
  • Figure 2. Europe Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Pharmacovigilance and Drug Safety Software Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. Europe Pharmacovigilance and Drug Safety Software Market Share (%) - by Offering (2023 and 2031)
  • Figure 6. Software: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 7. Services: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 8. Europe Pharmacovigilance and Drug Safety Software Market Share (%) - by Deployment (2023 and 2031)
  • Figure 9. Cloud: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 10. On Premises: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 11. Europe Pharmacovigilance and Drug Safety Software Market Share (%) - by Enterprise Size (2023 and 2031)
  • Figure 12. Large Enterprises: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 13. SMEs: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 14. Europe Pharmacovigilance and Drug Safety Software Market Share (%) - by Form (2023 and 2031)
  • Figure 15. Standard: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 16. Customized: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 17. Europe Pharmacovigilance and Drug Safety Software Market Share (%) - by Functionality (2023 and 2031)
  • Figure 18. Signal and Risk Management: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 19. Issue Tracking and Adverse Event Tracking: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 20. Case Management: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 21. Clinical Safety Management and Clinical Trial Safety: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 22. Quality and Compliance: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 23. Medical Writing: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 24. Audit Support and Training Compliance: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 25. Healthcare Analytics: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 26. Others: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 27. Europe Pharmacovigilance and Drug Safety Software Market Share (%) - by End User (2023 and 2031)
  • Figure 28. Pharmaceutical and Biotechnology Companies: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 29. Contract Research Organizations: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 30. Business Process Outsourcing (BPO) Firms: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 31. Others: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 32. Europe Pharmacovigilance and Drug Safety Software Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 33. Germany: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 34. France: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 35. United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 36. Italy: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 37. Spain: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 38. Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 39. Heat Map Analysis by Key Players
  • Figure 40. Company Positioning and Concentration